We have always devoted resources not only to staying on top of trends related to both doping and anti-doping, but also to anticipating the elusive ‘next big thing’.
Improving the detection of substances, longer window of detection, better identification of real contamination cases, and better analysis and reporting of substances of abuse, are among the areas on which we focus our efforts.
Here is a look at the past, present and future of some other developments in anti-doping led by WADA.
|
Area |
AKA… |
Past |
Present |
Future |
|
Matrices for anti-doping use |
Type of samples collected for analysis |
Detection in urine only |
Mainly urine with blood (from veins) for specific analyses (e.g. hGH, gene doping) |
Equal use of urine, blood and further development of Dried Blood Spot (DBS) testing for a larger number of substances
|
|
hGH |
Human Growth Hormone |
No detection method |
Method for direct and indirect (biomarkers) detection |
Direct detection and include biomarkers (indirect method) in the Athlete Biological Passport (ABP – blood module) with a longer detection window
|
|
Gene Doping |
Gene Doping |
No detection method |
Direct detection of transgene and some RNAs |
Integration of a full strategy to detect any form of gene doping by indirect methods (screening) and direct methods (confirmation)
|
|
AI |
Artificial Intelligence |
No application |
Pilot project in ABP modules for detection of abnormal profiles |
Full automated integration into ADAMS with automatic identification of abnormal profiles and alerts to ADOs
|
|
ABP |
Athlete Biological Passport |
No longitudinal individualized data analysis |
Hematological module established and endocrine module in development |
Integration of all modules (i.e. hematological, endocrine, performance) into ADAMS |